Serum biomarkers for improved diagnostic of pancreatic cancer: A current overview

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 3, 2011, Pages 375-389

  Bunger S ^a   Laubert, T ^a   Roblick, U J ^a,b   Habermann, J K ^a,b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Early detection; Pancreatic cancer screening; Serum biomarker; Serum diagnostics; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 195 ANTIGEN; CA 242 ANTIGEN; CA 50 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLONY STIMULATING FACTOR 1; GROWTH DIFFERENTIATION FACTOR 15; HAPTOGLOBIN; HEAT SHOCK PROTEIN 27; OSTEOPONTIN; PROTEIN CAM17.1; PROTEIN PAM4; SERUM AMYLOID A; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; TUMOR SPECIFIC GROWTH FACTOR; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; MEDLINE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SYSTEMATIC REVIEW; VALIDATION PROCESS;

EARLY DETECTION OF CANCER; HUMANS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79954430750     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0965-x     Document Type: Review

References (54)

1. Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini P (1993) Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chemxs 39:420-423 (Pubitemid 23099006)
2. Benson AB 3rd (2007) Adjuvant therapy for pancreatic cancer: one small step forward. JAMA 297:311-313 (Pubitemid 46143311)
3. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49:1-6 (Pubitemid 36078546)
4. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC et al (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29:365-371 (Pubitemid 34326681)
5. Brenner H, Hakulinen T (2009) Up-to-date cancer survival: period analysis and beyond. Int J Cancer 124:1384-1390
6. Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K (2006) Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 141:968-973; (discussion 974) (Pubitemid 44583251)
7. Duraker N, Hot S, Polat Y, Hobek A, Gencler N, Urhan N (2007) CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 95:142-147 (Pubitemid 46238983)
8. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S, Bogumil R, Buchler MW, Friess H (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34:205-214 (Pubitemid 46294796)
9. Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schutte C et al (2009) Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. Clin Cancer Res 15:3812-3819
10. Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ (2009) Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg 33:716-722
11. Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N, Nielsen HJ (2008) Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 23:42-47 (Pubitemid 351715544)
12. Galasso D, Carnuccio A, Larghi A (2010) Pancreatic cancer: diagnosis and endoscopic staging. Eur Rev Med Pharmacol Sci 14:375-385
13. Gansauge F, Gansauge S, Parker N, Beger MI, Poch B, Link KH, Safi F, Beger HG (1996) CAM 17.1-a new diagnostic marker in pancreatic cancer. Br J Cancer 74:1997-2002
14. Ghaneh P, Costello E, Neoptolemos JP (2007) Biology and management of pancreatic cancer. Gut 56:1134-1152 (Pubitemid 47123247)
15. Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban R, Goldenberg DM (2010) Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev
16. Goodwin RJ, Dungworth JC, Cobb SR, Pitt AR (2008) Timedependent evolution of tissue markers by MALDI-MS imaging. Proteomics 8:3801-3808
17. Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33:266-270 (Pubitemid 46488663)
18. Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, Mysliwiec P, Kedra B, Szmitkowski M (2007) Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin Chem Lab Med 45:30-34 (Pubitemid 46155556)
19. Haglund C, Lundin J, Kuusela P, Roberts PJ (1994) CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 70:487-492 (Pubitemid 24268552)
20. Holten-Andersen MN, Schrohl AS, Brunner N, Nielsen HJ, Hogdall CK, Hogdall EV (2003) Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers 18:170-176 (Pubitemid 37254281)
21. Jiang JT, Wu CP, Deng HF, Lu MY, Wu J, Zhang HY, Sun WH, Ji M (2004a) Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol 10:1675-1677 (Pubitemid 38786956)
22. Jiang XT, Tao HQ, Zou SC (2004b) Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 3:464-468
23. Joergensen MT, Brunner N, De Muckadell OB (2010) Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res 30:587-592
24. Katz MH, Hwang R, Fleming JB, Evans DB (2008) Tumor-nodemetastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 58:111-125
25. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH et al (2004a) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10:2386-2392 (Pubitemid 38445697)
26. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M (2004b) Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13:487-491 (Pubitemid 38737477)
27. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M (2006) Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12:442-446 (Pubitemid 43166133)
28. Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM (2007) Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 6:641-645
29. Liao WC, Wu MS, Wang HP, Tien YW, Lin JT (2009) Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas 38:422-426
30. Liu RC, Traverso LW (2005) Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 19:638-642 (Pubitemid 40898005)
31. Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG (2009) Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? J Am Coll Surg 208:87-95
32. McCarthy MJ, Evans J, Sagar G, Neoptolemos JP (1998) Prediction of resectability of pancreatic malignancy by computed tomography. Br J Surg 85:320-325 (Pubitemid 28098614)
33. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387-391 (Pubitemid 43080010)
34. McSweeney SE, O'Donoghue PM, Jhaveri K (2010) Current and emerging techniques in gastrointestinal imaging. J Postgrad Med 56:109-116
35. Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, Thieme H, Kaufmann R, Felix K, Friess HM et al (2007) Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem 53:629-635 (Pubitemid 46580232)
36. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G, Szmitkowski M (2009) Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 38:613-618
37. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q et al (2005) The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31:164-169 (Pubitemid 40214752)
38. Nieto J, Grossbard ML, Kozuch P (2008) Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13:562-576 (Pubitemid 351872873)
39. Ozkan H, Akar T, Koklu S, Coban S (2006) Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases. Pancreatology 6:268-272 (Pubitemid 44329077)
40. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava e (1994) A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Br J Cancer 69:562-565 (Pubitemid 24076480)
41. Pieragostino D, Petrucci F, Del Boccio P, Mantini D, Lugaresi A, Tiberio S, Onofrj M, Gambi D, Sacchetta P, Di Ilio C et al (2010) Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. J Proteomics 73:579-592
42. Rosch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV Jr, Yasuda K, Heyder N, Palazzo L, Dancygier H, Schusdziarra V et al (1992) Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 326:1721-1726
43. Rouy D, Ernens I, Jeanty C, Wagner DR (2005) Plasma storage at-80 degree C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 338:294-298 (Pubitemid 40312594)
44. Schrohl AS, Wurtz S, Kohn E, Banks RE, Nielsen HJ, Sweep FC, Brunner N (2008) Banking of biological fluids for studies of disease-associated protein biomarkers. Mol Cell Proteomics 7:2061-2066
45. Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 63:834-840
46. Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V et al (2007) CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34:436-443 (Pubitemid 46725785)
47. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607-2615 (Pubitemid 47041235)
48. Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K et al (2010) Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol 45:52-59
49. Taylor CF, Paton NW, Lilley KS, Binz PA, Julian RK Jr, Jones AR, Zhu W, Apweiler R, Aebersold R, Deutsch EW et al (2007) The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol 25:887-893 (Pubitemid 47236919)
50. Thurigen D, Spiegelman D, Blettner M, Heuer C, Brenner H (2000) Measurement error correction using validation data: a review of methods and their applicability in case-control studies. Stat Methods Med Res 9:447-474 (Pubitemid 32050883)
51. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L (2004) Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 49:1149-1155 (Pubitemid 39178081)
52. Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ (2006) Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis 7:170-174 (Pubitemid 43983749)
53. Yiannakou JY, Newland P, Calder F, Kingsnorth AN, Rhodes JM (1997) Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 349:389-392 (Pubitemid 27077667)
54. Zhao YP, Zhang TP (2008) Present status of and prospects for basic research on pancreatic cancer. Zhonghua Yi Xue Za Zhi 88:1945-1947